Peloton Therapeutics, Inc.
http://pelotontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Peloton Therapeutics, Inc.
Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC
Adjuvant renal cell carcinoma is a potentially lucrative indication for any checkpoint inhibitor; Merck & Co. flagship Keytruda is the first to demonstrate benefit in a Phase III study, although rivals are in pursuit.
Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.